University of Connecticut School of Medicine
Farmington, CT Medical Doctor College of the Holy Cross
POSTGRADUATE EDUCATION National Rehabilitation Hospital
Washington, DC Residency, Physical Medicine & Rehabilitation Georgia Baptist Medical Center
Atlanta, GA Internship, Transitional Year PROFESSIONAL EXPERIENCE
CLINICAL RESEARCH EXPERIENCE Protocol No. 3200A3-2201-US: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of ORAL MOA-728 for the treatment of opioid-induced bowel dysfunction in subjects with chronic non-malignant pain.12/2007 Protocol TD-07-14: The efficacy and safety of TDS-943 in the treatment of osteoarthritis of the knee: Pivotal Study II. 10/2007 KF5503/18 (Grunenthal); R331333-PAI-3010 (J&J PRD): Open-Label Extension, Single-Arm, Flexible-Dosing, Phase III Trial with CG5503 Extended-Release (ER) in Subjects with Moderate to Severe Chronic Pain. 11/2007 Protocol No. BUP3025: A Multi-center, Randomized, Double-blind, Placebo-controlled Study with an Open-label Run-in Assess the Efficacy, Tolerability, and Safety of BTDS 10 or BTDS 20 Compared to Placebo in Opioid-naïve Subjects with Moderate to Severe, Chronic Pain due to Osteoarthritis of the Knee. 10/2007 SPI/0211OBD-0631: A multi-center, Randomized, Placebo-Controlled, Double-Blinded Study of the Efficacy and Safety of Lubiprostone in Patients with Opioid-induced Bowel Dysfunction. 10/2007
SPI/0211OBD-06S1: A multicenter, open-labled study of the long-term Safety and Efficacy of Lubiprostone in Patients with Opioid-induced Bowel dysfunction. 2007 Protocol No. 3200K1-3356-WW: A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation in Subjects with Chronic Non-Malignant Pain. 2007 Penwest-Protocol NAL-20: Randomized, double blind placebo controlled dose escalation study of the analgesic efficacy of Nalbuphine-ER in patients with Chronic Pain Secondary to Osteoarthritis of the Knee/Hip. 2007 HTF919N2302, entitled “An open label 52-week study to evaluate the safety and efficacy of tegaserod (6 mg b.i.d. and 12 mg o.d.) given orally for the treatment of opioid-induced constipation (OIC) in patients with chronic non-cancer pain” Novartis) 2007 ALO-KNT-302. A Long-Term, Open-Label, Safety Study of Kadian NT (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects with Chronic Moderate to Severe Nonmalignant Pain. (Alpharma / INC Research) 2006 ALO-KNT-301. A Multicenter, Randomized, Placebo-Controlled, Phase 3 Efficacy Study of Kadian NT (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee. (Alpharma / INC Research) 2006 A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial with Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Subjects with Moderate to Severe Chronic Low Back Pain. Protocol KF5503/23(Grünenthal) R331333-PAI-3011 (J&JPRD): Johnson & Johnson 2007 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA- 728 For the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Non- Malignant Pain Wyeth Pharmaceuticals (3200A3-200-WW). Phase II. 2006 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study of the Efficacy, Tolerability and Safety of XXXX topical patch in the Treatment of Pain Associated with Tendonitis or Bursitis of the Shoulder, Elbow or Knee. EN3269-302. 2006 CCOX189A2367 A 13-week, multicenter, randomized, double-blind, double-dummy, placebo- controlled, parallel group trial of XXXX (COX189) 100 mg o.d. in patients with primary hip osteoarthritis using celecoxib (200 mg o.d.) as a positive control. (Novartis – PPD Development) 2005 - 2006 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of XXXX 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain. SB- 767905/012 2005 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long- Term Safety of XXXX 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain. SB-767905/014. 2005
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Week Study to Assess the Safety and Efficacy of HKT-500 in Subjects with Pain from Moderate Lateral Epicondylitis. HKT- 500-US05. 2005 A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Week Study to Assess the Safety and Efficacy of HKT-500 in Subjects with low back pain. HKT-500-US04. 2005 A Phase III Pivotal, Multi-center, Double-Blind, Randomized, Placebo-Controlled Monotherapy Study of (Study Drug) for Treatment of Fibromyaligia. Forest Laboratories / Scirex. (MLN-MD-02) 2004. A Randomized, Double-Blind, Placebo-Controlled, Multi-center Phase Ilb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimes for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Pain of Non-Malignant Origin. GlaxoSmithKline. (SB- 767905/011). 2004 - 2005 A Multicenter, Randomized, Double-Blind, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 and OxyIR® versus BTDS 5 in Subjects with Moderate to Severe Osteoarthritis (OA) Pain. Purdue Pharma. (BUP3019) 2004 -2005 Flexeril® Community Based Study. Kendle / McNeil. 3/2004 (Protocol 19-401). A Randomized, Parallel-Design, Multicenter Study To Evaluate The Efficacy of Avinza® vs Oxycontin® For The Treatment of Chronic Low Back Pain. Scirex / Organon (Protocol 178900) 2004 A 4 Week, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study of SD- 6010 in Subjects with Symptomatic Osteoarthritis of the Knee. (Protocol A6171009). Pfizer. January 2004. A Phase III, Randomized, Double-Blind, Fixed Dose, Parallel-Group Comparison of Controlled- Release Hydromorphone Hydrochloride (HCI) vs Placebo in Subjects with Osteoarthritis (Protocol M03-644). Abbott / Scirex January 2004. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of the Buprenorphine Transdermal Delivery System (BTDS) in Subjects with Moderate to Severe Osteoarthritic Pain of the Hip or Knee. Purdue Pharma. (BUP3012). 2003 - 2004 An Open-Label, Long-Term Effectiveness and Safety of Oxymorphone Extended Release Tablets in Patients with Cancer or Neuropathic Pain. Endo Pharmaceuticals Inc.,. (EN3202-029) 2003 - 2004
Dose Escalation of Active Comparator vs. Morphine in Opioid-Responsive Chronic Pain Patients (KND035). 2001 Cardiovascular Safety of Etoricoxib and Diclofenac in Patients With OsteoArthritis and Rheumatoid Arthritis 2002-2003
MK-0663 Protocol 072-00 (EDGE II) A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90mg Q.D. vs Diclofenac Sodium 75mg B.I.D. in Patients with Rheumatoid Arthritis 2003 A Usual Care, Multicenter, Open-Label, Randomized, 4-Month Parallel-Group Trial to Compare the Impact of Therapy with OxyContin ® (Controlled-Release Oxycodone) vs. Usual Care (Percocet ®) on Health Outcomes and Resource Utilization in Subjects with Moderate to Severe Osteoarthritis Pain of the Hip or Knee; 2002 Phase II Study on Analgesic Efficacy, Safety, and Tolerability of AZD3582: A 6 Week, Double Blind, Randomized, Placebo-Controlled, Dose-Finding, Multicentre Study Comparing AZD3582 with Rofecoxib (Vioxx ) in Subjects With Osteoarthritis of the Hip or Knee (ZEN010); 2002 A Multicenter, Randomized, Double-Blind, Active- and Placebo-Controlled. Phase II Dose Escalation, Efficacy and Safety Study of Oxycodone HCL and Low-Dose Naltrexone-HCL in Patients with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee (SCX038); 2002 A Double-Blind, Placebo Controlled, Parallel-Group, 12 Week Trial to Assess the Efficacy and Safety of XXX in Patients with Chronic Low Back Pain; 2000 PRESENTATIONS “Management of Fibromyalgia and Myofascial Pain Syndromes” Arthritis Foundation “Critical Illness Polyneuropathy: Long-term Functional Outcomes”, Grasso, A., Aseff, J., Gerber,L., National Rehabilitation Hospital Grand Rounds, June 1997. “Whiplash Syndrome: Diagnosis and Management,” National Rehabilitation Hospital, February 1997. “Elevated Erythrocyte Sedimentation Rate in a Paraplegic Patient who Developed a Deep Venous Thrombosis,” Rasul, A., Houston, J., Grasso, A., poster presentation, November 1995 AAPM&R Meeting. “Management of Scoliosis in Duchenne Muscular Dystrophy,” presented at Children’s National Medical Center, Department of Physical Medicine and Rehabilitation, September 1995. “Medical Complications in the Therapy Gym,” Conroy, B., Grasso, A., National Rehabilitation Hospital Physical & Occupational Therapy Grand Rounds, November 1994. “The post-occlusive fibrinolytic response in exercise trained and untrained quadriplegics,” Arnold, P., Nash, M., Grasso, A., Newington Children’s Hospital, 1993 Arnold, P., Farrell, W., McVey, P., Deurloo, T., Grasso, A., “Functional Electric Stimulation: It’s Efficacy and Safety in Improving Pulmonary Function and Musculoskeletal Fitness,” Archives of Physical Medicine and Rehabilitation, July 1992.
Grasso, A., Aller, S., Landsberg, J., Epstein, F., Forrest, J., Silva, P., “Neuropeptide Y Inhibits Chloride Secretion of the Rectal Gland of Squalus acanthias,” The Bulletin, Mount Desert Island
Biological Laboratory, vol. 29, 1990. LICENSES & CERTIFICATIONS American Board of Physical Medicine and Rehabilitation, certified May 1998 Diplomate, National Board of Medical Examiners, June 1994 Advanced Cardiac Life Support PROFESSIONAL MEMBERSHIPS & ACTIVITIES Physiatric Association of Spine, Sports and Occupational Rehabilitation American Academy of Physical Medicine and Rehabilitation Staff Physician, several local hospitals Speaker, Arthritis Foundation Public Health Education and Wellness Examinations Local High School Athletics Volunteer Physician
CME Renal Medicine on therapy in renal disease. Arch Intern Med 1981; 141 :1039–41. Richard S, Jothy S. A prospective study on Liam Plant MB MRCPI FRCPE, Consultant the impact of the renal biopsy in clinicalRenal Physician, Department of Renal management. Clin Nephrol 1986; 26 :217–21. 5 Cohen AH, Nast CC, Adler SG, Kopple JD. Medicine, Cork University Hospital, Cork, Clinica
Eisai London Research Laboratories Licenses OriGene’s FlagArrayTM for Genome-Wide Functional Analyses Rockville, MD August 1, 2005 – OriGene Technologies Inc. today announced that Eisai London Research Laboratories has licensed OriGene’s FlagArray platform for high-throughput drug target discovery. "We are pleased to formalize our relationship with OriGene,” said Yukio N